Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Ampion for COVID-19 Respiratory Distress
NCT04606784Phase 1Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing Ampion with Standard of Care (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 28. Started Oct 2020; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04606784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606784.